BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-20.37M |
| Operating Margin | 0.00% |
| Return on Equity | -106.40% |
| Return on Assets | -61.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.07 |
| Price-to-Book | 0.95 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.54M |
| Float | $7.50M |
| % Insiders | 0.36% |
| % Institutions | 13.94% |
Volatility is currently expanding
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.
CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the US Department of War, is testing whether bezisterim can address neurological and neuropsychiatric symptoms associated with Long COVID, including fatigue, cognitive dysfunction, post-exertional malaise and sleep disturbance.
-Topline Data Release Targeted Late Summer 2026- CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company's ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter. The NASDAQ-listed clinical-stage company said the completion of the final visit marks the start of the study closeout process.
Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026 Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026
CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how bezisterim's mechanism of action could potentially address the pathology and progression of neurodegenerative diseases, including Parkinson's disease. To register, click here.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday an abstract from its mid-stage study of experimental Parkinson's disease treatment bezisterim has been accepted for presentation at an upcoming neurology conference. The abstract, based on the company's SUNRISE-PD trial evaluating bezisterim in patients with early Parkinson's disease, will be presented at the American Academy of Neurology Annual Meeting later this week.
